Milgamma N (Thiamine Hydrochloride, Cyanocobalamin, Pyridoxine Hydrochloride)

Each vitamin acts as a co‑enzyme in essential metabolic pathways: thiamine assists carbohydrate breakdown, pyridoxine supports amino‑acid and neurotransmitter synthesis, and cyanocobalamin is crucial for DNA synthesis and myelin formation. Together they help restore normal metabolic and nervous system function.

The dosage of Milgamma N is determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of deficiency and response to therapy. The prescriber will specify the amount, frequency and duration of treatment.

Safety data for Milgamma N in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Milgamma N, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Milgamma N combines three essential B‑vitamins in a single injectable formulation, offering rapid systemic availability compared with oral supplements that may have variable absorption. This can be advantageous in acute deficiency states or when gastrointestinal absorption is impaired.

Milgamma N must be stored at 2‑8 °C, protected from light, and kept in its original packaging. It should not be frozen or shaken vigorously. Before administration, inspect the vial for particulate matter and ensure the solution is clear.

Milgamma N is given by intramuscular injection, typically into a large muscle such as the gluteus maximus. Administration should be performed by a qualified healthcare professional using aseptic technique.

Serious risks include anaphylactic reactions, severe hypotension, acute hemolysis in susceptible individuals, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for any signs of hypersensitivity during and after injection.

Milgamma N is contraindicated in individuals with known hypersensitivity to any of its components. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or those receiving medications that may interact significantly, such as methotrexate.